homepage-top-section

Pfizer has dosed the first subjects in a Phase I clinical trial to test an influenza vaccine which is developed using mRNA technology. The randomised Phase I trial,

The World Health Organization (WHO) has added Regeneron Pharmaceuticals and Roche’s Covid-19 antibody drug cocktail to the list of treatments for Covid-19 patients. The agency has recommended the

Tonix Pharmaceuticals has expanded its research partnership with Columbia University in the US for the development of tailored Covid-19 vaccines and treatments with precision medicine. The move follows

The US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for a booster dose of Pfizer-BioNTech’s Covid-19 vaccine. The regulatory agency approved the booster dose

German pharmaceutical firm Boehringer Ingelheim has acquired Abexxa Biologics to expand its research efforts in cancer immunology and novel immunotherapeutic approaches. The financial details of the transaction were

Pfizer and its partner BioNTech have announced positive topline results from a pivotal trial of their Covid-19 vaccine in children aged 5 to 11 years. The Phase II/III

Spanish healthcare firm Grifols has agreed to acquire 100% stake in Tiancheng (Germany) Pharmaceutical from Tiancheng International Investment for $1.289bn (€1.1bn). Tiancheng Pharmaceutical owns 89.88% of Biotest ordinary

Health Canada has granted full approval to Moderna’s Spikevax and Pfizer-BioNTech’s Comirnaty Covid-19 vaccines for use in individuals aged 12 years and above. The regulator originally authorised Moderna’s

Eli Lilly and Company has announced that the US government is set to purchase additional doses of its neutralising antibody therapy, etesevimab, to treat Covid-19. Under the terms